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Referral Center Experience With
Nonpalpable Contraceptive
Implant Removals
Melissa C. Matulich, MD, Melissa J. Chen, MD, MPH, Natasha R. Schimmoeller, MD, MPH,
Jennifer K. Hsia, MD, MPH, Suji Uhm, MD, MPH, Machelle D. Wilson, PhD, and Mitchell D. Creinin, MD
OBJECTIVE: To describe our experience with office
removal of nonpalpable contraceptive implants at our
referral center.
METHODS: We performed a retrospective cohort study
by reviewing the charts of patients referred to our family
planning specialty center for nonpalpable or complex
contraceptive implant removal from January 2015
through December 2018. We localized nonpalpable im-
plants using high-frequency ultrasonography and skin
mapping in radiology, followed by attempted removal in
the office using local anesthesia and a modified vasec-
tomy clamp. We abstracted information on demograph-
ics, implant location, and outcomes.
RESULTS: Of 61 referrals, 55 patients attended their
scheduled appointments. Seven patients had palpable
implants; six elected removal. The other 48 patients had
ultrasound localization, which identified 47 (98%) of the
implants; the remaining patient had successful localiza-
tion with computed tomography imaging. Nonpalpable
implants were suprafascial (n522), subfascial (n525) and
intrafascial (n51); four of these patients opted to delay
removal. Of 50 attempted office removals, all palpable
(n56), all nonpalpable suprafascial (n521 [100%, 95% CI
83–100%]), and 19 out of 23 (83%, 95% CI 67–98%) sub-
fascial implants were successful. Three of the four pa-
tients with failed subfascial implant office removal had
successful operating room removal with a collaborative
orthopedic surgeon; the other patient sought removal
elsewhere. Transient postprocedure neuropathic com-
plaints were noted in 7 out of 23 (30%, 95% CI 12–
49%) subfascial and 1 out of 21 (5%, 95% CI 0–13%)
suprafascial removals (P5.048). Nonpalpable implants
were more likely to be subfascial in nonobese patients
(24/34, 71%) as compared with obese (1/13, 8%) patients
(P,.001). Seven (28%) of the 25 subfascially located im-
plants had been inserted during a removal–reinsertion
procedure through the same incision.
CONCLUSION: Most nonpalpable contraceptive im-
plants can be removed in the office by an experienced
subspecialty health care provider after ultrasound local-
ization. Some patients may experience transient post-
procedure neuropathic pain. Nonpalpable implants in
thinner women are more likely to be in a subfascial
location.
(Obstet Gynecol 2019;134:801–6)
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Instructions for contraceptive subdermal implantinsertion have changed over the past decade, pri-
marily inspired by complications related to deep in-
sertions, including intravascular placement and
pulmonary artery migration.1–4 The most recent rec-
ommendation for optimal placement is between the
dermis and the subcutaneous tissue in the area of the
arm over the triceps muscle, with the intent
to minimize neurovascular injury should deep inser-
tion inadvertently occur.
Overall, major complications with insertion and
removal are exceedingly rare.5 Deep implant inser-
tions are estimated to occur approximately one out
of every 1,000 insertions,5,6 similar to the perforation
rate of intrauterine devices.7,8 Severe complications
associated with deep placement, such as intravascular
placement with pulmonary embolization, are esti-
mated to occur in just more than one patient per 1
million implants sold.4
Referral to a specialty center with physicians who
have expertise localizing and removing nonpalpable
implants is essential.9 Health care providers have
described various advanced techniques to localize
and remove nonpalpable implants6,9–16; however,
the reports typically only include descriptions with
a few patients and often involve costly resources such
as interventional radiology, fluoroscopy, and removal
in the operating room.6
In the United Kingdom, the Faculty of Sexual and
Reproductive Healthcare established a formal net-
work of expert removal centers more than a decade
ago17; however, only in the past few years has a similar
specialty removal network been developed in the
United States. This network is not outwardly adver-
tised by the etonogestrel implant manufacturer
(Merck & Co), and a comprehensive description of
the experience of any such specialty removal center
has never been presented. This report aims to
describe the experience of our fellowship-trained fam-
ily planning specialty division as a regional referral
center for nonpalpable implant removals. We aim to
describe our referral population, clinical outcomes
and what we have learned from caring for these pa-
tients. This information is important for all contracep-
tive providers to understand the complexity of such
a referral program, as well as the advanced techniques
and outcomes of nonpalpable implant removals.
METHODS
After obtaining institutional review board approval
from the University of California, Davis, we per-
formed a retrospective cohort study by reviewing our
implant referral clinical log to identify patients
referred to our family planning specialty clinic in the
Department of Obstetrics and Gynecology for non-
palpable or complex implant removal between Janu-
ary 2015 and December 2018. The first three patients
in this series have been previously reported.6 All pa-
tients were seen by a family planning fellow super-
vised by a family planning attending with fellowship
training in nonpalpable implant removals. Patients
referred to our program have an initial contact with
our family planning coordinator, who organizes
receipt of outside medical records and obtains insur-
ance authorization, often for out-of-network referral
and radiologic examinations. If insurance approval
is obtained, the patient has a concomitant appoint-
ment scheduled in our family planning clinic and radi-
ology for an upper extremity ultrasound examination.
For a typical appointment, the patient first meets with
the specialists who assess reasons for removal, ongo-
ing symptoms or problems related to any prior
removal attempts, and if the implant is palpable. Pa-
tients with nonpalpable, partially palpable or ques-
tionably palpable implants have ultrasound
localization in the radiology suite using a 15–18-
MHz linear array transducer to evaluate implant rela-
tionship to fascia and neurovascular structures; during
localization, the family planning specialists map the
implant location on the skin with a surgical marker
(Fig. 1). Implant removal then occurs in the office
using a technique we have previously described with
a modified vasectomy clamp under local anesthesia
through an incision that is typically about 5 mm or
less.6 While removing the implant, sharp instruments
are used only for skin and fascial incisions. Dissection
is performed with blunt forceps or a modified vasec-
tomy clamp. Patients with unsuccessful office removal
attempts are scheduled for an operating room
removal procedure with a collaborative orthopedic
surgeon. One of the family planning specialists assists
for implant identification, because the implant can
appear similar to neurovascular structures in the
upper arm.
We reviewed the electronic medical records of all
patients in our database during the study period to
abstract demographic information, medical histories,
implant specific data and clinical outcomes. Our
primary goal was to assess successful in-office removal
of the implant. We also evaluated the proportion of
patients referred compared with those seen in the
clinic as well as evaluation of the effect of body mass
index (BMI, calculated as weight in kilograms divided
by height in meters squared) and reinsertion of index
implant through removal incision on subfascial loca-
tion, and clinical outcomes including postprocedure
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complications. We arranged follow-up by phone or in
the office for women that had postprocedure com-
plaints until resolution or a diagnosis was made. We
used Fisher exact tests for dichotomous variables and t
test for continuous variables. We assessed normality
of age, BMI and distance traveled by histograms and
Q–Q plots; all data were normally distributed. All
data were analyzed with SAS 9.4.
RESULTS
Of 61 referrals, 55 (90%) patients presented for their
scheduled appointment; the characteristics are pre-
sented in Table 1. The median distance traveled was
20.8 miles (range 1.5–179 miles). The number of refer-
rals seen in the clinic annually increased from five in
2015 to 26 in 2018. Primary reasons for referral
included failed attempt at removal by the referring
health care provider (n529) for both palpable (n56)
and nonpalpable (n523) implants, or concern for
deeply placed, abnormally located or nonpalpable
implant without a removal attempt (n526). The num-
ber of patients experiencing at least one removal
attempt before referral remained constant at about
50% over the 4-year time period (2/5, 4/8, 10/16,
and 13/26 in 2015, 2016, 2017, and 2018, respectively).
Figure 2 outlines the outcomes of our assessments
and removal attempts. Overall, three patients with either
a palpable, intrafascial or suprafascial implant opted to
continue use after counseling, and two with subfascial
implants did not have removal attempts by our
team after initial evaluation. Of the 50 attempted office
Fig. 1. Skin mapping (A) and removal incision (B) of sub-
fascial implant in a patient with prior removal attempt by
general surgeon at outside institution.
Matulich. Nonpalpable Contraceptive Implant Removals. Obstet
Gynecol 2019.
Table 1. Demographic and Implant Characteristics
of Patients Evaluated for Nonpalpable or
Complex Implant Removal (N555)
Characteristic Value
Age (y) 26.765.8
Hispanic ethnicity 21 (38)
BMI (kg/m2) 28.369.1
Obese (BMI 30 or higher) 15 (27)
Parity
0 25 (46)
1 13 (24)
2 or more 16 (29)
Unknown or not recorded 1 (2)
Referral clinic
Reproductive health clinic* 24 (44)
Private office 26 (47)
Academic or internal 5 (9)
Distance traveled (miles)†
Less than 25 31 (56)
25–49 8 (15)
50–99 10 (18)
100 or more 6 (11)
Implant
Nexplanon 50 (91)
Implanon 5 (9)
Left arm 47 (86)
Right arm 8 (15)
Time from placement (mo) 30.3619.4
Prior contraceptive implant use
Yes 15 (27)
No 38 (69)
Unknown 2 (4)
Current implant inserted through removal incision
Yes 8 (53)
No 5 (33)
Unknown 2 (13)
Imaging before referral
None 30 (55)
1 imaging study (ultrasound or X-ray only) 17 (31)
Multiple imaging modalities 8 (15)
Removal attempts before referral
None 26 (47)
1 20 (36)
2 or more 9 (16)
Primary reason for removal
Device expiration 21 (38)
Desires pregnancy 8 (16)
Bleeding complaints 4 (7)
Systemic side effects 11 (20)
Other‡ 11 (18)
BMI, body mass index.
Data are mean6SD or n (%).
* Reproductive health clinic5Planned Parenthood or other com-
munity reproductive health clinic.
† Miles calculated from home ZIP code to clinic ZIP code using
Google Maps.
‡ Includes pain or neuropathy, location or migration concerns,
partially removed fragment, acute cellulitis, permanent contra-
ception initiated.
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removals, 46 (92%) were successful including all six pal-
pable implants and 40 out of 44 (91%) implants that
required ultrasound localization. Of the 44 nonpalpable
implants, successful removal rates for suprafascial im-
plants (21/21 [100%, 95% CI 83–100%]) did not differ
compared with subfascial implants (19/23 [83%, 95% CI
67–98%]), P5.11. Transient postprocedure neuropathic
complaints were noted in 7 out of 23 (30%, 95% CI 12–
49%) of the subfascial implant removals and 1 out of 21
(5%, 95% CI 0–13%) of the suprafascial implant remov-
als (P5.048). Neuropathic complaints included mild tin-
gling of fingers or numbness in ulnar distribution of arm.
These complaints all spontaneously resolved within 6
months, with the majority (6/8, 75%) resolving within
1 month. Of the 49 patients with successful in-office or
operating room removal, nine (18%) elected to have
another implant placed.
Table 2 compares the effect of BMI as a predictor
of subfascial location. Nonpalpable implants were
more likely to be subfascial in nonobese (24/34,
71%) patients as compared with obese (1/13, 8%) pa-
tients (P,.001). Fifteen patients referred to our
Fig. 2. Referral flowsheet of our clinical assessments and outcomes. OR, operating room. *Three patients opted to continue
use of implant: one palpable implant had 1 additional year of extended use; patient with intrafascial implant continued use
owing to time constraints after evaluation and counseling, aware she must return to specialty center at time of desired
removal; patient with suprafascial implant referred with acute cellulitis immediately after insertion, at consultation, cellulitis
was resolved and implant partially palpable (ultrasound localization confirmed implant location). †Two implants initially not
localized by ultrasound scan, identified using X-ray, repeat ultrasound scan located implants with minimal shadowing.
‡Subfascial implant identified with X-ray then localized with computed tomography; patient ultimately lost to follow-up
owing to insurance authorization issues. §One subfascial and one suprafascial implant required removal in ultrasound suite
for direct ultrasound guidance; all others were successfully removed with skin mapping technique in office.
Matulich. Nonpalpable Contraceptive Implant Removals. Obstet Gynecol 2019.
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specialty referral center had used a contraceptive
implant in the past, eight of whom were known to
have reinsertion of the index implant through the
removal incision. One of these implants was palpable
on our initial examination, and the other seven (88%)
were nonpalpable and subfascial. Six (86%) of the
seven nonpalpable subfascial implants were in pa-
tients with BMIs of less than 30.
DISCUSSION
At our family planning specialty referral center, 92%
of nonpalpable or complicated implants were success-
fully removed in the office. Importantly, we averted
a large incision in the operating room in 83% of those
with subfascial implants. However, nearly one-third of
these patients reported transient postprocedure neu-
ropathic complaints, albeit limited in duration; this
information should be incorporated into preproce-
dure counseling.
Our findings suggest that a nonpalpable implant
in nonobese patients is highly likely to be subfascial.
In these cases, health care providers without advanced
removal training should probably avoid attempting
removal and refer to a specialty center. Although our
data also suggest a potential association between
reinsertion through a removal incision and subfascial
placement, the analysis is limited owing to the small
numbers. To test this hypothesis the appropriate
comparison group would have to be a group of
women who had a second implant placed through
a separate incision. However, the link is plausible and
until additional data are available, health care pro-
viders should maintain caution when performing
a removal and reinsertion procedure.
More than 50% of our patients had prior removal
attempts before referral, with 16% having had two or
more failed attempts. We expected this proportion to
decrease over time as the community grew more
aware of our specialty center; however, the rates
remained stable. Clearly, more targeted education
for clinic staff, health care providers, and patients is
warranted. The U.S. Food and Drug Administration–
mandated implant insertion and removal training
would provide an excellent opportunity for education
about early referral for nonpalpable or deep implants,
and we encourage that specific information about the
U.S. specialty removal network be added to the
program.
We use ultrasonography for primary implant
localization, which provides the ability to mark the
position of the implant and identify nearby vascular
structures. Transducers with a frequency of 5 or 7.5
MHz, which are commonly available in an obstetri-
cian-gynecologist’s office, can be used to identify cor-
rectly placed implants.18 Frequencies of 10 MHz or
greater are more useful with nonpalpable implants,
because these frequencies can identify an implant in
both suprafascial and subfascial locations.19 We have
found that newer 15- and 18-MHz transducers, which
are developed primarily for extremity visualization,
are an important tool, especially for subfascial
implants.
Our outcomes confirm the utility of high-
frequency ultrasound localization of nonpalpable im-
plants and demonstrate the importance of a specialty
referral center for removal. Our experience with
subfascial implant removal in the office is unique.
We were obligated to develop this process owing to
scheduling limitations for implant removals under
direct ultrasound guidance in the radiology suite.
Because deep implant placement is rare, this report
represents a relatively large series. Still, the numbers
are too small to support any predictive multivariable
analyses.
Our outcomes provide essential information for
all clinicians who see patients using contraceptive
implants to ensure appropriate counseling and
decision-making when removal is desired and the
implant is not easily palpable. Health care providers
who cannot easily palpate the implant at the time of
Table 2. Comparison of Body Mass Index, Reinsertion and Removal Event, and Reasons for Removal
Between Suprafascial Nonpalpable and Subfascial Nonpalpable Implants
Nonpalpable Suprafascial (n522) Nonpalpable Subfascial (n525) P*
BMI (kg/m2) 34.069.4 23.163.8 ,.001
BMI category ,.001
Underweight to normal (less than 25) 4 (18) 17 (68)
Overweight (25 to less than 30) 6 (27) 7 (28)
Obese (30 or higher) 12 (55) 1 (4)
BMI, body mass index.
Data are mean6SD or n (%) unless otherwise specified.
* t-test used for means, and Fisher exact test used for categorical comparisons.
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requested removal should consider early referral to
a specialty center. When the location of such a center
is unknown, pharmaceutical company representatives
should be contacted for more information.
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